Yves Moreau is a professor at KU Leuven ESAT STADIUS.

His team focuses on AI algorithms and software platforms for the integration of complex data in clinical genomics and drug discovery:

1. federated analysis of real-world clinical and genomic data,
2. data fusion algorithms for the identification of pathogenic genetic variation in rare genetic disorders and liquid biopsies, and
3. data fusion for drug discovery and drug design.

At the algorithmic level, Prof. Moreau focuses on the development of novel AI methods, such as deep learning and Bayesian matrix factorization, for the fusion of heterogeneous sparsely-observed data; and on privacy-preserving implementations of such methods. He aims at demonstrated clinical or industrial applicability of his methods and proven effectiveness in human genetics research and drug discovery.

Prof. Moreau is engaged in a reflection on how information technology and artificial intelligence are transforming our world and on how to make sure this transformation is beneficial for all. In particular, I am actively pushing back against the emergence of surveillance societies that has been made possible by such technological advances.

Prof. Moreau is am also a tech innovator interested in identifying relevant business models for emerging technologies and developing projects up to the precompetitive stage and the startup of university spin-offs. He is a co-founder of Data4S, a data mining company specialized in fraud detection and anti-moneylaundering, which is now part of BAE Systems, Detica NetReveal. He is also a co-founder of Cartagenia (taken over by Agilent Technologies), specialized in ICT solutions for clinical genetic diagnosis.